70 related articles for article (PubMed ID: 26641303)
1. Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance.
Wartha F; Horn AH; Meiselbach H; Sticht H
J Chem Theory Comput; 2005 Mar; 1(2):315-24. PubMed ID: 26641303
[TBL] [Abstract][Full Text] [Related]
2. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Vasavi CS; Tamizhselvi R; Munusami P
J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
[TBL] [Abstract][Full Text] [Related]
4. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
5. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
6. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
8. Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.
Bastys T; Gapsys V; Walter H; Heger E; Doncheva NT; Kaiser R; de Groot BL; Kalinina OV
Retrovirology; 2020 May; 17(1):13. PubMed ID: 32430025
[TBL] [Abstract][Full Text] [Related]
9. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.
Bihani SC; Gupta GD; Hosur MV
J Biomol Struct Dyn; 2022; 40(23):13127-13135. PubMed ID: 34609269
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
12. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
13. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
14. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
16. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
[TBL] [Abstract][Full Text] [Related]
17. Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants.
Purohit R; Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2011 Aug; 29(1):137-52. PubMed ID: 21696230
[TBL] [Abstract][Full Text] [Related]
18. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
19. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
20. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.
Ode H; Matsuyama S; Hata M; Neya S; Kakizawa J; Sugiura W; Hoshino T
J Mol Biol; 2007 Jul; 370(3):598-607. PubMed ID: 17524421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
